 German vaccine developer, CureVac N.V. NASDAQ: CVAC, may not be as fortunate as its domestic peer BioNTech SE NASDAQ: BNTX, which along with its U.S. partner Pfizer, Inc. NYSE: PFE, has found resounding success with its vaccine program. 